



Do You or Someone You Love Have Alzheimer's Disease?

Consider Participating in the SIGNAL-AD Trial



SIGNAL-AD is a clinical study of an investigational drug called *pepinemab*. The study will evaluate the drug's safety profile, brain imaging effects and potential effects on cognition in people with early Alzheimer's disease (AD).

Learn more about pepinemab at www.Vaccinex.com

Study assessments, testing and medication are provided at no cost to participants.

You may be eligible if you:

- ✓ Are 55 to 85 years old
- ✓ Have been diagnosed with early Alzheimer's disease
- ✓ Have a trial partner who will support you and participate in the study

Learn more about the study:

- ◆ **Speak with your doctor**
- ◆ **Visit ClinicalTrials.gov where you can:**
 - **Read study details**
 - **See who can take part**
 - **Find study locations**

Pepinemab is an investigational drug currently in clinical studies. It has not been demonstrated to be safe and effective for any disease indication, including Alzheimer's disease. There is no guarantee that pepinemab will be approved for the treatment of any disease by the U.S. Food and Drug Administration or by any other health authority worldwide.

Study Sponsor
VACCINEX